皮膚科四谷（ヨツヤ）みどりの森ひふ科クリニック

JR四ッ谷駅前皮膚科専門医　all copyright (C)GREEN FOREST DERMATOLOGY CLINIC ALL RIGTS RESERDVED.

［メディア掲載］

・毎日新聞 3面（2005年10月18日）

・日経産業新聞　11面（2005年10月24日）

［発表論文］

最近の論文

① Yazawa N, Fujimoto M, Tamaki K. Recent advances on pathogenesis and therapies in systemic sclerosis. Clin Rev Allergy Immunol. 2007;33:107-12.

主な発表論文

① Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA. 2005;102:15178-83.
② Yazawa N, Fujimoto M, Sato S, Miyake K, Asano N, Nagai Y, Takeuchi O, Takeda K, Okochi H, Akira S, Tedder TF, Tamaki K.CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood. 2003 ;102:1374-80.

その他の論文（英文のみ）全61編

1: Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N, Echigo T, Okochi H, Tamaki K.  Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.　J Dermatol Sci. 2008 ;49:153-61.
2: Prazma CM, Yazawa N, Fujimoto Y, Fujimoto M, Tedder TF.　CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo.J Immunol. 2007 ;179:4550-62.
3: Watanabe R, Ishiura N, Nakashima H, Yazawa N, Kuwano Y, Tada Y, Okochi H, Fujimoto M, Tamaki K.　Increased serum levels of circulating CD40 ligand in patients with bullous pemphigoid: preliminary results.　Dermatology. 2007 ;215:180-6.
4: Kuwano Y, Prazma CM, Yazawa N, Watanabe R, Ishiura N, Kumanogoh A, Okochi H, Tamaki K, Fujimoto M, Tedder TF.　CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells.　Int Immunol. 2007 ;19:977-92.
5: Watanabe R, Fujimoto M, Ishiura N, Kuwano Y, Nakashima H, Yazawa N, Okochi H, Sato S, Tedder TF, Tamaki K.　CD19 expression in B cells is important for suppression of contact hypersensitivity.　Am J Pathol. 2007 ;171:560-70. 
6: Kuwano Y, Fujimoto M, Watanabe R, Ishiura N, Nakashima H, Ohno Y, Yano S, Yazawa N, Okochi H, Tamaki K.　Serum chemokine profiles in patients with alopecia areata.　Br J Dermatol. 2007 ;157:466-73.
7: Mimura Y, Yazawa N, Tada Y, Ihn H, Tamaki K.Anti-p53 antibodies in patients with systemic sclerosis.　Int J Dermatol. 2007 ;46:549-50.
8: Izumi R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Watanabe R, Kuwano Y, Kurokawa M, Hashimoto T, Tamaki K.　Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.J Am Acad Dermatol. 2007 ;56(5 Suppl):S94-7.　
9: Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K, Tamaki K.High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma.　Br J Dermatol. 2007 ;156:1058-60. 
10: Nakashima H, Fujimoto M, Asashima N, Watanabe R, Kuwano Y, Yazawa N, Maruyama N, Okochi H, Kumanogoh A, Tamaki K.　Serum chemokine profile in patients with bullous pemphigoid.　Br J Dermatol. 2007 ;156:454-9.
11: Watanabe R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Kuwano Y, Tada Y, Maruyama N, Okochi H, Tamaki K.　Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid.　J Dermatol Sci. 2007 ;46:53-60. 
12: Kuwano Y, Fujimoto M, Watanabe R, Asashima N, Nakashima H, Ohno H, Yano S, Yazawa N, Okochi H, Tamaki K.　Serum anti-Fcgamma receptor autoantibodies in patients with alopecia areata.　Arch Dermatol Res. 2007 ;298:493-8.
13: Mimura Y, Yazawa N, Tamaki Z, Ashida R, Jinnin M, Asano Y, Tada Y, Kubo M, Ihn H, Tamaki K.　Anti-p53 antibodies in patients with dermatomyositis/polymyositis.Clin Rheumatol. 2007 ;26:1328-31. 
15: Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, Tamaki K.　Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris.　Br J Dermatol. 2006 ;155:330-6.1: 
16: Kikuchi K, Hoashi T, Yazawa N, Tamaki K.Pseudoscleroderma associated with cancer.　Clin Exp Dermatol. 2006 ;31:381-3. 
17: Kuwano Y, Ihn H, Yazawa N, Kakinuma T, Asahina A, Kikuchi K, Tamaki K.Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin.Acta Derm Venereol. 2006 ;86:158-9. 
18: Mimra Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K.Anti-agalactosyl immunoglobulin G antibodies in localized scleroderma.Int J Dermatol. 2005 ;44:817-20. 
19: Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K.Sclerosing panniculitis is associated with pulmonary hypertension in systemic sclerosis. Br J Dermatol. 2005 ;153:579-83. 
20: Jinnin M, Ihn H, Yazawa N, Tamaki K. Serum levels of manganese superoxide dismutase in patients with mixed connective tissue disease.Clin Exp Rheumatol. 2005 ;23:549-50. 
21: Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K.Serum levels of anti-agalactosyl IgG antibodies in mixed connective tissue disease.Br J Dermatol. 2005 ;152:806-7.
22:   Asano Y, Ihn H, Asashima N, Yazawa N, Mimura Y, Jinnin M, Yamane K,Tamaki K. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion.Rheumatology (Oxford). 2005 ;44:824-6. 
23: Fujimoto M, Hamaguchi Y, Yazawa N, Komura K, Takehara K, Sato S.　Autoantibodies to a collagen-specific molecular chaperone, heat-shock protein 47, in systemic sclerosis.Clin Exp Immunol. 2004 ;138:534-9. 
24: Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.Br J Dermatol. 2004 ;151:803-8. 
25:  Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N., Tamaki K. Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis. Br J Dermatol. 2004 ;151:407-12.
26:  Asano N, Fujimoto M, Yazawa N., Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S.  B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.Am J Pathol. 2004 ;165:641-50.
27:  Jinnin M, Ihn H, Yazawa N., Asano Y, Yamane K, Tamaki K.  Serum levels of manganese superoxide dismutase in patients with localized scleroderma. Exp Dermatol. 2004 ;13:357-60.
28:  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N., Tamaki K. Serum matrix metalloproteinase-3 in systemic sclerosis.Arch Dermatol Res. 2004 ;296:25-9.
29:  Jinnin M, Ihn H, Yazawa N., Asano Y, Yamane K, Tamaki K.  Elevated serum levels of manganese superoxide dismutase in patients with eosinophilic fasciitis.  Clin Rheumatol. 2003 ;22:505. 
30:  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N., Tamaki K.  Effect of D-penicillamine on pulmonary fibrosis in patients with systemic sclerosis. Ann Rheum Dis. 2003 ;62:1019-20. 
31:  Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N., Tamaki K. Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis.  Clin Exp Rheumatol. 2003 ;21:91-4.
32:  Jinnin M, Ihn H, Yazawa N., Asano Y, Yamane K, Tamaki K.  Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. Clin Rheumatol. 2003 ;22:37-9.
33:  Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N., Tamaki K.  Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension.Rheumatology (Oxford). 2003 ;42:240-3.
34:  Jinnin M, Ihn H, Yazawa N., Asano Y, Yamane K, Tamaki K.  Circulating soluble CD40 ligand in patients with eosinophilic fasciitis. Ann Rheum Dis. 2003 ;62:190-1. 
35:  Ihn H, Asano Y, Kubo M, Yamane K, Jinnin M, Yazawa N., Fujimoto M, Tamaki K. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.Rheumatology (Oxford). 2002 ;41:1268-72.
36:  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N., Tamaki K. 　Autoimmune response to 52-kDa and 60-kDa Ro/SS-A antigens in mixed connective tissue disease.　Br J Dermatol. 2002 ;147:827-9.
37:  Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N., Tamaki K.  Serum levels of tissue inhibitor of metalloproteinases in patients with mixed connective tissue disease.Clin Exp Rheumatol. 2002 ;20:539-42.
38:  Kubo M, Ihn H, Asano Y, Yamane K, Yazawa N., Tamaki K.  Prevalence of 52-kd and 60-kd Ro/SS-A autoantibodies in Japanese patients with polymyositis/dermatomyositis.  J Am Acad Dermatol. 2002 ;47:148-51.
39:  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N., Tamaki K.  A case of linear scleroderma with muscle calcification.Br J Dermatol. 2002 ;146:1084-6.
40:  Soma Y, Mizoguchi M, Yamane K, Yazawa N., Kubo M, Ihn H, Kikuchi K, Tamaki K. Specific inhibition of human skin fibroblast chemotaxis to platelet-derived growth factor A-chain homodimer by transforming growth factor-beta1. Arch Dermatol Res. 2002 ;293:609-13. 
41:  Yamane K, Ihn H, Kubo M, Asano Y, Yazawa N., Tamaki K.  Anti-U3 snRNP antibodies in localised scleroderma. Ann Rheum Dis. 2001 ;60:1157-8. 
42:  Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N., Tamaki K.Anti-U1RNP antibodies in patients with localized scieroderma. Arch Dermatol Res. 2001 ;293:455-9.
43:  Kubo M, Ihn H, Kuwana M, Yamane K, Yazawa N., Tamaki K. Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin. Clin Exp Immunol. 2001 ;126:339-44.
44:  Yazawa N., Ihn H, Yamane K, Kubo M, Fujimoto M, Kikuchi K, Soma Y, Tamaki K. Elevated circulating soluble CD30 levels in patients with polymyositis/dermatomyositis. Br J Dermatol. 2001 ;145:676-8. 
45:  Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N., Tamaki K. Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma.Rheumatology (Oxford). 2001 ;40:683-6.
46:  Asano Y, Ihn H, Yamane K, Yazawa N., Kubo M, Fujimoto M, Tamaki K. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.Arthritis Rheum. 2001 ;44:1363-9.
47:  Kubo M, Ihn H, Yamane K, Yazawa N., Kikuchi K, Soma Y, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis. Br J Dermatol. 2000 ;143:392-8.
48:  Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N., Soma Y, Tamaki K. Serum KL-6 in adult patients with polymyositis and dermatomyositis.Rheumatology (Oxford). 2000 ;39:632-6.
49:  Yamane K, Ihn H, Kubo M, Yazawa N., Kikuchi K, Soma Y, Tamaki K. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.J Rheumatol. 2000 ;27:930-4.
50:  Ihn H, Yazawa N., Kubo M, Yamane K, Sato S, Fujimoto M, Kikuchi K, Soma Y, Tamaki K.    Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.J Rheumatol. 2000 ;27:698-702.
51:  Yazawa N., Kikuchi K, Ihn H, Fujimoto M, Kubo M, Tamaki T, Tamaki K. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis.J Am Acad Dermatol. 2000 ;42:70-5.
52:  Yamane K, Ihn H, Kubo M, Yazawa N., Kikuchi K, Soma Y, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma.J Am Acad Dermatol. 2000 ;42:64-9.
53:  Ihn H, Sato S, Fujimoto M, Igarashi A, Yazawa N., Kubo M, Kikuchi K, Takehara K, Tamaki K.Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol. 2000 ;119:203-9.
54:  Ihn H, Yamane K, Yazawa N., Kubo M, Fujimoto M, Sato S, Kikuchi K, Tamaki K.Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol. 1999 ;11:383-7.
55:  Kubo M, Ihn H, Yazawa N., Sato S, Kikuchi K, Tamaki K. Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. J Invest Dermatol. 1999 ;112:711-5.
56:  Kikuchi K, Kubo M, Kadono T, Yazawa N., IHN H, Tamaki K.  Serum concentrations of vascular endothelial growth factor in collagen diseases.Br J Dermatol.1998 ;139:1049-51.
57:  Kubo M, Kikuchi K, Yazawa N., Fujimoto M, Tamaki T, Tamaki K.Increased serum concentration of hyaluronate in dermatomyositis patients. Arch Dermatol Res. 1998 ;290(10):579-81. 
58:  Sato S, Hasegawa M, Nagaoka T, Takamatsu Y, Yazawa N., Ihn H, Kikuchi K, Takehara K.   Autoantibodies against calpastatin in sera from patients with systemic sclerosis. J Rheumatol. 1998 ;25:2135-9.
59:  Yazawa N., Fujimoto M, Kikuchi K, Kubo M, Ihn H, Sato S, Tamaki T, Tamaki K. High seroprevalence of Helicobacter pylori infection in patients with systemic sclerosis: association with esophageal involvement. J Rheumatol. 1998 ;25:650-3.
60:  Fujimoto M, Kikuchi K, Tamaki T, Yazawa N., Kubo M, Ihn H, Sato S, Soma Y, Tamaki K. Distribution of anti-p80-coilin autoantibody in collagen diseases and various skin diseases. Br J Dermatol. 1997 ;137:916-20.
61:  Fujimoto M, Shimozuma M, Yazawa N., Kubo M, Ihn H, Sato S, Tamaki T, Kikuchi K, Tamaki K.  Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis.Ann Rheum Dis. 1997 ;56:667-70.

皮膚科 四谷（ヨツヤ） みどりの森ひふ科クリニック

皮膚科四谷（ヨツヤ）みどりの森ひふ科クリニック